Drug-drug Interaction Study with AZD5305 and Itraconazole in Patients with Advanced Solid Malignancies

Study identifier:D9720C00005

ClinicalTrials.gov identifier:NCT05573724

EudraCT identifier:2022-001450-33

CTIS identifier:N/A

Study Complete

Official Title

A Non-randomized, Open-label, Fixed-sequence Phase I Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD5305 in Patients with Advanced Solid Malignancies

Medical condition

Advanced solid malignancies

Phase

Phase 1

Healthy volunteers

No

Study drug

Itraconazole, AZD5305

Sex

All

Actual Enrollment

16

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 07 Nov 2022
Primary Completion Date: 17 Apr 2023
Study Completion Date: 17 May 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria